Effect of Baclofen in Management of Patients With Gastroesophageal Reflux Disease Symptoms

NCT ID: NCT07063576

Last Updated: 2025-08-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2/PHASE3

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-01

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to assess the effect of using baclofen along with conventional treatment in improving GERD symptoms. It will also assess the safety of drug baclofen by recording the patient reported adverse events. The main questions it aims to answer are :

Does drug baclofen along with conventional treatment has any effect on patients with GERD symptoms? What medical problems do participants have when taking drug baclofen? Researcher will compare drug baclofen along with conventional treatment to a control group taking placebo along with conventional treatment.

Participants will:

Take drug baclofen 10 milligrams or placebo three times daily along with conventional treatment for 4 weeks. They will visit the hospital after 4 weeks. Their symptoms will be assessed via validated GERD Q questionnaire at baseline and after 4 weeks. Additionally, patient reported adverse events will be documented.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

GERD - PPI Non-responders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Baclofen

Tablet baclofen 10mg three times will be given along with conventional treatment

Group Type ACTIVE_COMPARATOR

Baclofen 10mg

Intervention Type DRUG

Tablet baclofen 10mg three times daily along with conventional treatment

Placebo

Tablet placebo three times daily along with conventional treatment

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Tablet placebo three times daily along with conventional treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Baclofen 10mg

Tablet baclofen 10mg three times daily along with conventional treatment

Intervention Type DRUG

Placebo

Tablet placebo three times daily along with conventional treatment

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 and above
* Patients with persistent GERD symptoms (Heart burn and/or regurgitation) despite taking conventional treatment including PPI for 8 weeks

Exclusion Criteria

* GERD symptoms with any alarming features (dysphagia, weight loss, bleeding, vomiting, and/or anemia)
* Baseline GERD Q score less than 8
* Peptic gastric or duodenal ulcer on endoscopy
* Other esophageal disease like achalasia, carcinoma, corrosive stricture
* Gastrointestinal malignancy
* History of major gastrointestinal surgery
* Medical disease that affects the esophageal or gastric motility, such as uncontrolled diabetes, hyperthyroidism, hypothyroidism
* Patient with renal impairment
* Pregnant and lactating women
* Use of drugs affecting on LES
* Regular use of drug that may interact with Baclofen
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Adnan Imtiaj Rahul

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Adnan Imtiaj Rahul

Principal investigator

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dhaka Medical College

Dhaka, , Bangladesh

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Bangladesh

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Adnan Imtiaj Rahul, MBBS

Role: CONTACT

+8801311286376

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB-DMC/2025/70

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Gracie Diet for Gastroesophageal Reflux Disease
NCT04360252 ACTIVE_NOT_RECRUITING NA